An investigational amylin analogue studied alone and combined with semaglutide as CagriSema. Phase 2 complete; phase 3 REDEFINE programme reporting.
Cagrilintide copies amylin, a hormone released alongside insulin from the pancreas after eating. Amylin's job is to signal fullness, slow the stomach and reduce how much glucagon the body releases. It works on a different pathway from GLP-1, which is why researchers pair the two — the combination targets two separate satiety signals at once. It is not approved and remains investigational.
Cagrilintide is a long-acting acylated analogue of human amylin, engineered from a hybrid of human and salmon calcitonin sequences to prevent the amyloid fibrillation that makes native human amylin unsuitable as a drug. A C20 fatty diacid provides albumin binding and weekly dosing. It is a non-selective agonist across the amylin receptor family — heterodimers of the calcitonin receptor with receptor activity-modifying proteins RAMP1, RAMP2 and RAMP3 (AMY1, AMY2, AMY3) — and also activates the calcitonin receptor directly. Satiety signalling is mediated in the area postrema and nucleus tractus solitarius, anatomically and pharmacologically distinct from GLP-1R-mediated satiety. That separation is the rationale for co-formulation with semaglutide as CagriSema: two non-overlapping anorectic pathways with additive effect.
Research areas
Community-specified data
Source note: Same titration as semaglutide. Min 0.25mg / Max 2.4mg
Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.
Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.
| Protocol as reported | Source |
|---|---|
| Weekly subcutaneous doses escalated to maintenance arms of 0.3, 0.6, 1.2, 2.4 or 4.5 mg over 26 weeks | Lau et al., The Lancet 2021 (phase 2 monotherapy protocol) |
| 2.4 mg cagrilintide with 2.4 mg semaglutide, weekly, as the CagriSema combination | CagriSema phase 2 trial protocol (Frias et al., The Lancet 2023) |
Phase 2 complete as monotherapy and in combination with semaglutide. Phase 3 REDEFINE programme underway with initial results reported.
706 adults with overweight or obesity. Dose-dependent mean weight reductions of 6.0% to 10.8% across 0.3–4.5 mg arms vs 3.0% on placebo at 26 weeks.
92 participants. Combination produced greater HbA1c and weight reduction than either component alone at 32 weeks.
Multiple registered phase 3 trials of CagriSema in obesity and type 2 diabetes.
Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
Discovery of the once-weekly amylin analogue cagrilintide
Medical disclaimer
This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.
How this profile was built →